Source: Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017



Rating:

Share or cite this content

Citations should be made in the following way:
Stefano Ponzano, Giulia Nigrelli, Laura Fregonese, Irmgard Eichler, Fabio Bertozzi, Tiziano Bandiera, Luis J.V. Galietta, Marisa Papaluca. A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators. Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017

Member's Comments

No comment yet.

Related content which might interest you: ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020 The era of CFTR modulators: improvements made and remaining challenges Source: Breathe, 16 (2) 200016; 10.1183/20734735.0016-2020 Year: 2020 CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways Source: Eur Respir Rev, 29 (156) 190068; 10.1183/16000617.0068-2019 Year: 2020 Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy Source: Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021 Year: 2021 Gene therapy for cystic fibrosis: successes and challenges Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=79 Year: 2006 The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications Source: Virtual Congress 2020 – Respiratory infections Year: 2020 Treatment of interstitial lung diseases: current approaches and future directions Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 Idiopathic pulmonary fibrosis: current challenges and future perspectives Source: Eur Respir Rev 2013; 22: 103-105 Year: 2013 Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013 How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment Source: International Congress 2016 – Closing the gap: novel translational research strategies Year: 2016 Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017 Year: 2017 Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients? Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020 Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Pharmacological treatment of the biochemical defect in cystic fibrosis airways Source: Eur Respir J 2001; 17: 1314-1321 Year: 2001 CF clinical care and its delivery: current and future challenges Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission Year: 2019